ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
24. Juli 2024 04:00 ET | AKAMPION
Dosing of patients in new combination treatment arm – IOS-1002 plus KEYTRUDA Schlieren (Zurich Area), Switzerland – July 24, 2024 – ImmunOs Therapeutics AG, a biopharmaceutical company using its...
Anaveon_dark_blue_logo high res.jpg
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
29. Mai 2024 02:00 ET | Anaveon
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA
17. Oktober 2023 04:00 ET | AKAMPION
- Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors   ...
1ST Biotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate FB849 in Combination With KEYTRUDA® (pembrolizumab)
19. September 2023 04:00 ET | AKAMPION
YONGIN, South Korea, September 19, 2023 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative...
Logo.jpg
Final Results for the year ended 31 December 2020
01. April 2021 07:00 ET | 4D Pharma PLC
Leeds, UK, April 01, 2021 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD, NASDAQ: LBPS) (“4D”, the “Company” or, together with its subsidiaries, the “Group”), a pharmaceutical company leading the...
provectus_logo.jpg
Provectus Biopharmceuticals Highlights Stage IV M1d Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Refractory Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020
21. September 2020 14:05 ET | Provectus Biopharmaceuticals Inc.
Complete response of all injected lesionsRegression of non-injected inguinal node, lung, and brain metastasesExpanded data set of trial subject provided KNOXVILLE, TN, Sept. 21, 2020 (GLOBE...
provectus_logo.jpg
Provectus Biopharmaceuticals Announces Presentation of Preliminary Data from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Refractory Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020
17. September 2020 07:00 ET | Provectus Biopharmaceuticals Inc.
36% ORR and 64% DCR (RECIST 1.1)PV-10-induced, tumor-specific restoration of T cell functionData compare favorably to approved and investigational therapies for patient population KNOXVILLE, TN,...
provectus_logo.jpg
PV-10-based Cancer Combination Therapy Clinical Trial Design Wins Australasian Gastro-Intestinal Trials Group’s New Concepts Award
27. August 2019 09:00 ET | Provectus Biopharmaceuticals Inc.
Two-stage, 34-patient, Phase 2 study combines PV-10 and Keytruda® (pembrolizumab) for treatment of metastatic neuroendocrine tumorsCombination powered for 19% ORR vs 3.7% ORR for Keytruda...
provectus_logo.jpg
PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON MELANOMA CLINICAL DEVELOPMENT PROGRAM FOR INVESTIGATIONAL DRUG PV-10
06. Dezember 2018 08:30 ET | Provectus Biopharmaceuticals Inc.
Lesion-level response data from main cohort of advanced melanoma patients naïve to immune checkpoint inhibition in Phase 1b/2 combination study of PV-10 and KEYTRUDA® (pembrolizumab) presented at...
provectus_logo.jpg
PROVECTUS BIOPHARMACEUTICALS COMPLETES ENROLLMENT OF PHASE 1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA® IN PATIENTS WITH METASTATIC MELANOMA
07. Mai 2018 08:00 ET | Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Data presentation planned for first half of 2019 KNOXVILLE, TN, May 07, 2018 (GLOBE NEWSWIRE) -- Provectus today announced the completion of enrollment of 24 patients...